Drug intelligence / Profile preview

VNX-208

Development stage: Preclinical
Lead developer: Vironexis Biotherapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies

Overview

VNX-208 is an investigational AAV-delivered T-cell immuno-gene therapy developed by Vironexis Biotherapeutics for the treatment of non-small cell lung cancer (NSCLC). Built on the proprietary TransJoin™ platform, VNX-208 utilizes an adeno-associated virus (AAV) vector to deliver genetic instructions directly into the patient's cells *in vivo*. This gene delivery enables the endogenous production of therapeutic proteins that act as "bridges," connecting the patient's T cells to specific antigens on NSCLC cells to trigger a targeted immune response. This approach aims to provide the efficacy of T-cell engaging therapies without the need for complex ex vivo cell manufacturing or intensive conditioning regimens.

Beyond the preview

Go deeper on VNX-208.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNX-208.

Explore the full profile